Bristol Myers Squibb receives European Commission approval for Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma

BMS

19 August 2021 - Abecma represents the only cell therapy approved for multiple myeloma.

Bristol Myers Squibb today announced that the European Commission has granted conditional marketing authorisation for Abecma (idecabtagene vicleucel), a first-in-class B-cell maturation antigen directed chimeric antigen receptor T cell immunotherapy, for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

Read BMS press release

Michael Wonder

Posted by:

Michael Wonder